title: Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib.
abstract: OBJECTIVE
  To Characterize a new human lung cancer cell line Am1010, derived from drug-surviving cells (DSCs).
  
  
  METHODS
  The Am1010 cell line was established after 4 cycles of chemotherapy from an arm muscle metastatic tumor of a patient diagnosed with lung adenocarcinoma. The cell line has been remained in continuous culture for more than one year during this study.
  
  
  RESULTS
  The Am1010 cell line demonstrated in vitro multi-drug-resistance to cisplatin, taxol, and gefitinib. The Am1010 cell doubling time without drug treatment was 42.395 h. The IC(50) value of cisplatin was 4.299 micromol/L and >10 micromol/L for the Am1010 and P0318 (a cell line derived from non-DSCs) cells, respectively. The IC(50) value of taxol was 0.067 micromol/L and >1 micromol/L for the Am1010 and P0318 cells, respectively. The IC(50) value of gefitinib was 15.233 micromol/L and >70 micromol/L for Am1010 and P0318 cells, respectively. 11 genes involved in the focal adhesion and cell adhesion pathways were found to be differentially expressed. The cells of Am1010 have a significantly larger chromosome number than most lung cancer cell lines.
  
  
  CONCLUSIONS
  This novel DSCs derived lung cancer cell line will be a valuable in vitro tool for the investigation of lung cancer drug resistance and metastasis.
authors.affiliation: Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease, The 1st Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, China.
authors.forename: Hui-ling
authors.initials: HL
authors.lastname: Li
authors.forename: Si-ming
authors.initials: SM
authors.lastname: Xie
authors.forename: Liang
authors.initials: L
authors.lastname: Zhang
authors.forename: Cheng-jie
authors.initials: CJ
authors.lastname: Cai
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Jun
authors.initials: J
authors.lastname: Huang
authors.forename: Dao-yuan
authors.initials: DY
authors.lastname: Wang
authors.forename: Dan-ping
authors.initials: DP
authors.lastname: Wen
authors.forename: Qiu-hua
authors.initials: QH
authors.lastname: Deng
authors.forename: Nan-shan
authors.initials: NS
authors.lastname: Zhong
authors.forename: Jian-xing
authors.initials: JX
authors.lastname: He
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000818:Animals; D045744:Cell Line, Tumor / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation; D002875:Chromosomes / Q000235:genetics; D002945:Cisplatin / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D000077156:Gefitinib; D020869:Gene Expression Profiling; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D051379:Mice; D008819:Mice, Nude; D017239:Paclitaxel / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*
chemical_list: D011799:Quinazolines; D017239:Paclitaxel; D002945:Cisplatin; D000077156:Gefitinib